Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 5
2000 3
2001 4
2002 3
2003 7
2004 5
2005 5
2006 7
2007 13
2008 10
2009 9
2010 8
2011 10
2012 13
2013 11
2014 17
2015 15
2016 23
2017 21
2018 16
2019 14
2020 20
2021 18
2022 20
2023 12
2024 18
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.
Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J. Lim JS, et al. Among authors: wislez m. Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10. Nature. 2017. PMID: 28489825 Free PMC article.
[Pulmonary sarcomatoid carcinoma].
Antoine M, Vieira T, Fallet V, Hamard C, Duruisseaux M, Cadranel J, Wislez M. Antoine M, et al. Among authors: wislez m. Ann Pathol. 2016 Jan;36(1):44-54. doi: 10.1016/j.annpat.2015.11.007. Epub 2016 Jan 8. Ann Pathol. 2016. PMID: 26778815 Review. French.
[Bronchoalveolar carcinoma].
Wislez M, Cadranel J, Milleron B. Wislez M, et al. Rev Prat. 2003 Apr 1;53(7):743-6. Rev Prat. 2003. PMID: 12879797 Review. French.
[Pulmonary sarcomatoid carcinoma].
Vieira T, Duruisseaux M, Ruppert AM, Cadranel J, Antoine M, Wislez M. Vieira T, et al. Among authors: wislez m. Bull Cancer. 2012 Oct;99(10):995-1001. doi: 10.1684/bdc.2012.1619. Bull Cancer. 2012. PMID: 22889810 Review. French.
Primary pulmonary lymphoma.
Cadranel J, Wislez M, Antoine M. Cadranel J, et al. Among authors: wislez m. Eur Respir J. 2002 Sep;20(3):750-62. doi: 10.1183/09031936.02.00404102. Eur Respir J. 2002. PMID: 12358356 Free article. Review.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: wislez m. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
279 results